Skip to main content
Premium Trial:

Request an Annual Quote

Tet Systems Acquires Patent Rights from AMC

NEW YORK (GenomeWeb News) – Tet Systems has acquired from The Academic Medical Center (AMC) and the Technology Foundation STW in the Netherlands the rights to use and commercialize gene expression-related Tet technologies covered by eight patent applications.

Tet Systems’ technologies are used to provide reversible control over the timing and level of gene expression in eukaryotic cells. These tools have been used in tissue and culture systems and in organisms such as yeasts, protozoans, insects, amphibians, plants, and mammals. They enable detailed analyses of complex biological processes such as behavior, development, and disease.

“The existing scientific relationship between our researchers at AMC and the inventors of the Tet Technology formed the basis for the new IP generated at AMC and led to this agreement with Tet Systems,” Joris Heus, of AMC’s Technology Transfer Office, said in a statement.

“With the acquisition of these patent applications from AMC and STW, we broadened our IP portfolio and the rights to the core Tet Technology are again unified and can now be offered to our existing licensees and new interested parties,” Ernst Boehnlein, CEO of Tet Systems, added.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.